UNSPSC 51182710: Metformin/linagliptin

Metformin/linagliptin is a combination of an agent of the biguanide class and a DPP-4 inhibitor used to treat high blood sugar levels caused by type 2 diabetes.

UNSPSC 51182710 Metformin/linagliptin, a Commodity code, shows no relevant recent state and local procurement activity. The recent-opportunities block contains one pharmaceutical solicitation (Naloxone and Safe Drug Deactivation Systems for Seminole County, Florida, an IFB posted June 30, 2026), a multi-state cooperative pharmaceutical RFP (MMCAP Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026), and a multi-jurisdictional EMS pharmaceutical and supplies procurement (City of Tucson Fire Department, RFP posted June 24, 2026), but none of these solicitations reference metformin or linagliptin or diabetes management pharmaceuticals. The remaining records in the block are vendor forums, trade shows, networking events, relocation notices, and survey requests—none related to pharmaceutical procurement.

The code does not reflect current state and local buying patterns. To assess whether metformin/linagliptin procurement occurs under this code at the state and local level, monitor issuing bodies with established health plan, employee wellness, emergency medical services, or public health pharmacy programs—counties and municipalities with in-house clinics, transit authorities with occupational health services, and state health departments—but no recent solicitation activity supports active pursuit in the short term.